Smart Money · Holder IQ
54.5 / 100
Above median holder quality (percentile 53.3 this quarter).
ATYR
aTyr Pharma, Inc.NASDAQ
$6.11-1.69%
Close Nov 13, 2026
Reading stored signals…
Healthcare • Biotechnology
Company Quality Grade
Per-share book value with reinvested dividends, and the steadiness of its 40-quarter trend.
As of · Window to
Historical book-value growth with dividends
- Book with dividends · annual growth
- -18.1%
- Consistency of fitted trend · R²
- 0.356
- Recent / whole-window slope
- 2.68×
- ATYR
- Whole-window fit
- Recent 12-quarter fit
Quarterly chart values · 41 observations
· 100 indexed · 3.6 per share
· 85.5 indexed · 3.1 per share
· 72.5 indexed · 2.6 per share
· 58.4 indexed · 2.1 per share
· 46 indexed · 1.7 per share
· 66.6 indexed · 2.4 per share
· 59.1 indexed · 2.2 per share
· 50.1 indexed · 1.8 per share
· 41.6 indexed · 1.5 per share
· 35.8 indexed · 1.3 per share
· 30.1 indexed · 1.1 per share
· 334 indexed · 12.2 per share
· 234.5 indexed · 8.6 per share
· 188.3 indexed · 6.9 per share
· 149.1 indexed · 5.4 per share
· 123.4 indexed · 4.5 per share
· 105.4 indexed · 3.8 per share
· 88.2 indexed · 3.2 per share
· 78.7 indexed · 2.9 per share
· 85 indexed · 3.1 per share
· 68.8 indexed · 2.5 per share
· 115.9 indexed · 4.2 per share
· 107.7 indexed · 3.9 per share
· 96.2 indexed · 3.5 per share
· 84.4 indexed · 3.1 per share
· 72.9 indexed · 2.7 per share
· 66.4 indexed · 2.4 per share
· 56.4 indexed · 2.1 per share
· 51 indexed · 1.9 per share
· 46 indexed · 1.7 per share
· 39.2 indexed · 1.4 per share
· 33.9 indexed · 1.2 per share
· 29.5 indexed · 1.1 per share
· 23.6 indexed · 0.9 per share
· 22.8 indexed · 0.8 per share
· 23.1 indexed · 0.8 per share
· 22.1 indexed · 0.8 per share
· 22.4 indexed · 0.8 per share
· 18.9 indexed · 0.7 per share
· 16.2 indexed · 0.6 per share
· 13.6 indexed · 0.5 per share
Basis: tangible common book. Dividends are reinvested at book value.
No decline detected by the published slope-ratio test.
Method, filing sources and publication receipt
The compounder rule requires a top-decile composite, positive slope and no detected decline in the tangible-book eligible pool. Total-common-book fallback rows cannot qualify. Decline means the 90% interval for recent / whole-window slope lies below 1.
Source: SEC first-filed XBRL. Midas Edge API’s published Green Compounders method uses only filings public by the as-of date, split-adjusted shares and the original filed values. Restatements do not replace them. Issuer pools and entity types reflect the SEC submissions captured for this run, not historical classifications at each as-of date.
The primary form fits log book value with reinvested dividends against time. The method checks the starting book and market-cap floors and excludes identified non-reliance/enforcement windows. Its cohort is fixed at capture time, so historical percentiles have capture and survival limits. It does not check audit-opinion going-concern text. This grade is separate from InsiderIQ, HolderIQ and NetCredibility.
Input filings (41 in this window): 0000950170-22-017401; 0000950170-22-024724; 0000950170-23-007873. The links show up to three of the input filings.
Method notes: Going-concern audit wording was not evaluated. Missing dividend facts were treated as zero by the published method. No preferred-equity fact was filed; the method used zero. Enforcement findings use records naming the issuer. The history contains a large unexplained tangible-book decline. Some quarters use weighted-average shares.
- Parameters
- pg-g2-params.v36
- Plane
- sha256:b08311b44a364243079bd02d05184590ce1b4a8cecae5ac54eb47e6d8d100282
- Grade row SHA-256
- sha256:d6489fa7e974de9e026d924b18ff942433f73478917e521c1945b93653d78c50
- Manifest SHA-256
- sha256:a759396dbafa0c13c8b128c70452c491b5de054e46821a357c30bd15b13ce27f
- Engine SHA-256
- sha256:59cafdcf1cf34b8d7549562af91a81cf1204405ccf03224493f1228e71293258
- Hand-check receipt SHA-256
- sha256:1eb90c6040524e68ca2ed0a0feab58b3e77fa52586a2872887a9be00ed2a52b7
- Market cap
- $15.23Mas of Nov 12, 2026
- 1 month
- -17.0%
- 3 months
- -70.6%
- 1 year
- -78.9%
More market facts
- Dividend
- No dividends on record
- Latest-quarter EPS estimate
- -$4.00Quarter ended Sep 30, 2026 · 7 analysts · -3,900.0% in 30d
- Short interest
- 293.4K sharessettled Oct 30, 2026 · FINRA
Estimate history · same fiscal quarter
Quarter ended Sep 30, 2026. Source: Stored analyst estimates.
| Observed / analysts | EPS | Revenue |
|---|---|---|
| 7 analysts | -4.00 | — |
| 7 analysts | -4.00 | — |
| 7 analysts | -0.10 | — |
| 7 analysts | -0.10 | — |
| 7 analysts | -0.1014 | — |
| 7 analysts | -0.1014 | — |
Dates identify stored observations, not earnings announcements. Gaps do not mean estimates were unchanged. The analyst group and vendor earnings basis may change.
Link an account to see your stake, watchlist and past holdings. Compare changes in earnings expectations with your investment case. These are analyst estimates, not reported results or a prediction of your return.
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $190K
- Net income
- -$60.81M
- Free cash flow
- -$54.82M
- Book value
- $48.79M
- Total debt
- $11.3M
- P/E
- —
- Price / sales
- 80.1×
- Price / book
- 0.3×
- FCF yield
- -360.1%
- Net margin
- -32,003.7%
Trailing twelve-month statements · as of Nov 13, 2026 · multiples on the Nov 12, 2026 market cap
End-of-day close from stored market data, not a live quote.
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
Read more
Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
- Website
- atyrpharma.com
- Headquarters
- San Diego, CA, United States
- Employees
- 58
- Listed
- May 7, 2015
- Fiscal year ends
- December
Company profile stored Oct 26, 2026.
Quarterly results
The last 8 fiscal quarters from the latest stored normalized financial statements. These may include restatements. Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 7, 2026 | — | — | — | -$10.9M | -$10.3M |
| Mar 2026filed May 15, 2026 | — | — | — | -$11.4M | -$10.8M |
| Dec 2025filed Mar 5, 2026 | — | — | — | -$14.8M | -$14.0M |
| Sep 2025filed Nov 6, 2025 | $190.0K | — | -11,547.4% | -$26.7M | -$25.7M |
| Jun 2025filed Aug 7, 2025 | — | — | — | -$20.3M | -$19.5M |
| Mar 2025filed May 7, 2025 | — | — | — | -$15.8M | -$14.9M |
| Dec 2024filed Mar 13, 2025 | — | — | — | -$15.8M | -$15.0M |
| Sep 2024filed Nov 7, 2024 | — | — | — | -$18.1M | -$17.3M |
Balance sheet · cash, debt and near-term obligations
What resources sit beside the obligations? These are balances at each fiscal quarter end, not cash earned during the quarter. Amounts are in USD, the reporting currency.
As of
- Reported cash
- $16.2M
- Reported total debt
- $11.3M
- Current assets
- $58.4M
- Current liabilities
- $11.4M
Vendor filing date:
As of
- Reported cash
- $10.0M
- Reported total debt
- $11.7M
- Current assets
- $67.6M
- Current liabilities
- $11.7M
Vendor filing date:
As of
- Reported cash
- $10.7M
- Reported total debt
- $12.0M
- Current assets
- $80.2M
- Current liabilities
- $15.1M
Vendor filing date:
As of
- Reported cash
- $6.2M
- Reported total debt
- $12.4M
- Current assets
- $93.0M
- Current liabilities
- $15.7M
Vendor filing date:
Link an account to see your stake, watchlist and past holdings. Compare cash and debt across dates when reviewing its reliance on financing. Current assets can include receivables and inventory; current liabilities include bills as well as borrowings. They are not all spendable cash or all debt. These figures alone do not establish the ability to repay.
Source: the latest stored normalized balance sheets, matched to the same security and fiscal end as these income periods. They may include restatements and are not an originally-filed or knowledge-time history. No net debt, coverage ratio or replacement balance is calculated. Read the SEC guide to financial statements for the distinction between balances and cash flows.
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 5, 2026 | $190.0K | -19.1% | -717.4% | -$77.6M | -$74.1M |
| Dec 2024filed Mar 13, 2025 | $235.0K | -33.4% | — | -$67.9M | -$64.0M |
| Dec 2023filed Mar 14, 2024 | $353.0K | — | — | -$54.9M | -$50.4M |
| Dec 2022filed Mar 14, 2023 | — | — | — | — | — |
| Dec 2021filed Mar 15, 2022 | — | — | — | -$34.0M | -$33.8M |
| Dec 2020filed Mar 24, 2021 | — | — | — | — | — |
Annual cash generation
Does profit turn into cash? Compare ATYR’s accounting profit with operating cash flow and capital spending. Amounts are in USD.
Fiscal year ending
- Net income
- -$74.1M
- Operating cash flow
- -$62.0M
- Capital spending
- $77.0K
- Free cash flow
- -$62.1M
Fiscal year ending
- Net income
- -$64.0M
- Operating cash flow
- -$69.1M
- Capital spending
- $65.0K
- Free cash flow
- -$69.2M
Fiscal year ending
- Net income
- -$50.4M
- Operating cash flow
- -$33.2M
- Capital spending
- $4.2M
- Free cash flow
- -$37.4M
Earlier cash-flow years
Fiscal year ending
- Operating cash flow
- -$41.9M
- Capital spending
- $1.6M
- Free cash flow
- -$43.5M
Fiscal year ending
- Net income
- -$33.8M
- Operating cash flow
- -$33.1M
- Capital spending
- $192.0K
- Free cash flow
- -$33.3M
Fiscal year ending
- Operating cash flow
- -$15.3M
- Capital spending
- $202.0K
- Free cash flow
- -$15.5M
Link an account to see your stake, watchlist and past holdings. Compare cash generation and investment needs with your thesis. Working capital and non-cash charges can separate profit from cash. Capital spending can reduce free cash flow while earnings rise. For a long or short position, that gap alone does not predict a price move.
Cash-flow source and meaning
Source: Annual financial statements, latest stored vendor-normalized figures. These may include restatements and may differ from the filer’s own XBRL. A filing date is not the knowledge date of this version of the values.
Free cash flow is the vendor’s reported figure, shown only when it agrees with operating cash flow less capital spending recorded as a positive outflow. It is not cash guaranteed for dividends or buybacks, and it does not subtract every financing obligation. Missing or sign-incompatible inputs are not filled in. An unlabelled currency is used only for a confirmed domestic USD filer. These are annual statements, not forecasts or an originally-filed history.
Cash allocation: dividends, shares and debt
Where did ATYR’s financing cash go? Compare cash paid as dividends with net share and debt transactions across fiscal years. Amounts are in USD, the reporting currency. These are company-wide totals, not per-share payouts.
Fiscal year ended
Vendor filing date:
- Net borrowing / repayment
- -$539.0K
- Total financing cash flow
- $66.0M
Fiscal year ended
Vendor filing date:
- Net borrowing / repayment
- -$497.0K
- Total financing cash flow
- $39.9M
Fiscal year ended
Vendor filing date:
- Net borrowing / repayment
- -$394.0K
- Total financing cash flow
- $66.2M
Fiscal year ended
Vendor filing date:
- Net borrowing / repayment
- -$66.0K
- Total financing cash flow
- $5.5M
Fiscal year ended
Vendor filing date:
- Net borrowing / repayment
- $0.0
- Total financing cash flow
- $110.0M
Fiscal year ended
Vendor filing date:
- Total financing cash flow
- $16.1M
Link an account to see your stake, watchlist and past holdings. Compare these uses of cash with operating cash generation and the debt on the balance sheet. A negative net share movement means purchases exceeded issuance; it does not give gross buybacks. A dividend or share purchase can be financed with borrowing, and none of these flows guarantees a future payment or price return.
Allocation source and sign conventions
Source: Annual cash-flow statements, latest stored vendor-normalized values for the same security and fiscal year. These can include restatements; a filing date is not the knowledge date of this version.
Dividends are positive cash paid out. For net share transactions, net borrowing and total financing, positive means cash in and negative means cash out. Net share transactions combine issuance and purchases; they are not gross repurchases, a change in shares outstanding, or stock compensation. Total financing includes other flows and is not the sum of just these three lines. Zero means a reported zero. No FX conversion, shareholder-return total or forecast is inferred.
Short-interest history
Reported short positions, stored float percentages and adjusted prices over the same period.
Shares short
Share of float
Adjusted close · USD
Settlement records · 58 observations
Settlement Oct 30, 2026
293,448 shares short
Published Nov 10, 2026.
Settlement Oct 15, 2026
10,273,700 shares short
-2,619,308 shares (-20.3%) vs Sep 30, 2026
10.5% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
12,893,008 shares short
+2,224,851 shares (+20.9%) vs Sep 15, 2026
13.2% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
10,668,157 shares short
+1,389,124 shares (+15%) vs Aug 31, 2026
11.2% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
9,279,033 shares short
-162,369 shares (-1.7%) vs Aug 14, 2026
9.7% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
9,441,402 shares short
-284,654 shares (-2.9%) vs Jul 31, 2026
Published Aug 25, 2026.
Settlement Jul 31, 2026
9,726,056 shares short
+1,448,650 shares (+17.5%) vs Jul 15, 2026
Published Aug 11, 2026.
Settlement Jul 15, 2026
8,277,406 shares short
-6,227,670 shares (-42.9%) vs Jun 30, 2026
Published Jul 24, 2026.
Settlement Jun 30, 2026
14,505,076 shares short
-4,006,641 shares (-21.6%) vs Jun 15, 2026
Published Jul 10, 2026.
Settlement Jun 15, 2026
18,511,717 shares short
-1,676,689 shares (-8.3%) vs May 29, 2026
Published Jun 25, 2026.
Settlement May 29, 2026
20,188,406 shares short
-1,205,755 shares (-5.6%) vs May 15, 2026
Published Jun 9, 2026.
Settlement May 15, 2026
21,394,161 shares short
+1,549,108 shares (+7.8%) vs Apr 30, 2026
Published May 27, 2026.
Settlement Apr 30, 2026
19,845,053 shares short
-39,082 shares (-0.2%) vs Apr 15, 2026
Published May 11, 2026.
Settlement Apr 15, 2026
19,884,135 shares short
+266,972 shares (+1.4%) vs Mar 31, 2026
Published Apr 24, 2026.
Settlement Mar 31, 2026
19,617,163 shares short
+649,661 shares (+3.4%) vs Mar 13, 2026
Published Apr 10, 2026.
Settlement Mar 13, 2026
18,967,502 shares short
+165,142 shares (+0.9%) vs Feb 27, 2026
Published Mar 24, 2026.
Settlement Feb 27, 2026
18,802,360 shares short
-1,075,006 shares (-5.4%) vs Feb 13, 2026
Published Mar 10, 2026.
Settlement Feb 13, 2026
19,877,366 shares short
-555,605 shares (-2.7%) vs Jan 30, 2026
Published Feb 25, 2026.
Settlement Jan 30, 2026
20,432,971 shares short
-901,080 shares (-4.2%) vs Jan 15, 2026
Published Feb 10, 2026.
Settlement Jan 15, 2026
21,334,051 shares short
-3,679,806 shares (-14.7%) vs Dec 31, 2025
Published Jan 27, 2026.
Settlement Dec 31, 2025
25,013,857 shares short
-5,371,709 shares (-17.7%) vs Dec 15, 2025
Published Jan 12, 2026.
Settlement Dec 15, 2025
30,385,566 shares short
+584,474 shares (+2%) vs Nov 28, 2025
Published Dec 24, 2025.
Settlement Nov 28, 2025
29,801,092 shares short
-63,550 shares (-0.2%) vs Nov 14, 2025
Published Dec 9, 2025.
Settlement Nov 14, 2025
29,864,642 shares short
-1,196,096 shares (-3.9%) vs Oct 31, 2025
Published Nov 25, 2025.
Settlement Oct 31, 2025
31,060,738 shares short
-5,081,855 shares (-14.1%) vs Oct 15, 2025
Published Nov 11, 2025.
Settlement Oct 15, 2025
36,142,593 shares short
-1,789,776 shares (-4.7%) vs Sep 30, 2025
Published Oct 24, 2025.
Settlement Sep 30, 2025
37,932,369 shares short
+4,843,276 shares (+14.6%) vs Sep 15, 2025
Published Oct 9, 2025.
Settlement Sep 15, 2025
33,089,093 shares short
+3,683,983 shares (+12.5%) vs Aug 29, 2025
Published Sep 24, 2025.
Settlement Aug 29, 2025
29,405,110 shares short
+1,159,978 shares (+4.1%) vs Aug 15, 2025
Published Sep 10, 2025.
Settlement Aug 15, 2025
28,245,132 shares short
+2,646,750 shares (+10.3%) vs Jul 31, 2025
Published Aug 26, 2025.
Settlement Jul 31, 2025
25,598,382 shares short
+5,216,512 shares (+25.6%) vs Jul 15, 2025
Published Aug 11, 2025.
Settlement Jul 15, 2025
20,381,870 shares short
+1,917,165 shares (+10.4%) vs Jun 30, 2025
Published Jul 24, 2025.
Settlement Jun 30, 2025
18,464,705 shares short
+4,819,752 shares (+35.3%) vs Jun 13, 2025
Published Jul 10, 2025.
Settlement Jun 13, 2025
13,644,953 shares short
-125,196 shares (-0.9%) vs May 30, 2025
Published Jun 25, 2025.
Settlement May 30, 2025
13,770,149 shares short
+1,088,848 shares (+8.6%) vs May 15, 2025
Published Jun 10, 2025.
Settlement May 15, 2025
12,681,301 shares short
+990,074 shares (+8.5%) vs Apr 30, 2025
Published May 27, 2025.
Settlement Apr 30, 2025
11,691,227 shares short
+1,666,057 shares (+16.6%) vs Apr 15, 2025
Published May 9, 2025.
Settlement Apr 15, 2025
10,025,170 shares short
+1,703,144 shares (+20.5%) vs Mar 31, 2025
Published Apr 25, 2025.
Settlement Mar 31, 2025
8,322,026 shares short
+1,401,517 shares (+20.3%) vs Mar 14, 2025
Published Apr 9, 2025.
Settlement Mar 14, 2025
6,920,509 shares short
+1,661,481 shares (+31.6%) vs Feb 28, 2025
Published Mar 25, 2025.
Settlement Feb 28, 2025
5,259,028 shares short
+904,088 shares (+20.8%) vs Feb 14, 2025
Published Mar 11, 2025.
Settlement Feb 14, 2025
4,354,940 shares short
+538,210 shares (+14.1%) vs Jan 31, 2025
Published Feb 26, 2025.
Settlement Jan 31, 2025
3,816,730 shares short
+300,873 shares (+8.6%) vs Jan 15, 2025
Published Feb 11, 2025.
Settlement Jan 15, 2025
3,515,857 shares short
-131,169 shares (-3.6%) vs Dec 31, 2024
Published Jan 27, 2025.
Settlement Dec 31, 2024
3,647,026 shares short
+726,956 shares (+24.9%) vs Dec 13, 2024
Published Jan 10, 2025.
Settlement Dec 13, 2024
2,920,070 shares short
+746,245 shares (+34.3%) vs Nov 29, 2024
Published Dec 24, 2024.
Settlement Nov 29, 2024
2,173,825 shares short
+59,449 shares (+2.8%) vs Nov 15, 2024
Published Dec 10, 2024.
Settlement Nov 15, 2024
2,114,376 shares short
+452,376 shares (+27.2%) vs Oct 31, 2024
Published Nov 26, 2024.
Settlement Oct 31, 2024
1,662,000 shares short
+596,636 shares (+56%) vs Oct 15, 2024
Published Nov 11, 2024.
Settlement Oct 15, 2024
1,065,364 shares short
-299,515 shares (-21.9%) vs Sep 30, 2024
Published Oct 24, 2024.
Settlement Sep 30, 2024
1,364,879 shares short
+679,100 shares (+99%) vs Sep 13, 2024
Published Oct 9, 2024.
Settlement Sep 13, 2024
685,779 shares short
+244,907 shares (+55.6%) vs Aug 30, 2024
Published Sep 24, 2024.
Settlement Aug 30, 2024
440,872 shares short
+94,114 shares (+27.1%) vs Aug 15, 2024
Published Sep 11, 2024.
Settlement Aug 15, 2024
346,758 shares short
+76,206 shares (+28.2%) vs Jul 31, 2024
Published Aug 26, 2024.
Settlement Jul 31, 2024
270,552 shares short
-66,034 shares (-19.6%) vs Jul 15, 2024
Published Aug 9, 2024.
Settlement Jul 15, 2024
336,586 shares short
-55,893 shares (-14.2%) vs Jun 28, 2024
Published Jul 24, 2024.
Settlement Jun 28, 2024
392,479 shares short
+115,959 shares (+41.9%) vs Jun 14, 2024
Published Jul 10, 2024.
Settlement Jun 14, 2024
276,520 shares short
Published Jun 26, 2024.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records. Adjusted prices exclude a reused ticker’s earlier issuer. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
Through Nov 14, 2026
Recorded amounts and dates, not confirmation of cash received.
View all 2 splits
| Ex-date | Event | Recorded detail |
|---|---|---|
| Oct 29, 2026 | Reverse split | 1 for 40Each 40 pre-split shares become 1 post-split share. |
| Jul 1, 2019 | Reverse split | 1 for 14Each 14 pre-split shares become 1 post-split share. |
Cash bars retain the event's recorded currency and share basis. The yield line divides recorded cash in the preceding 365 days, adjusted for intervening splits, by a verified raw close in the same currency. Special dividends are included. Future ex-dates are excluded from yield. A split changes share count, not investment value. For long shares, past entitlement depends on when you held them; short shares can create a dividend payment obligation.
Source: recorded cash-dividend and split events.
Portfolio context
Link an account to see your stake, watchlist and past holdings.
We’ll show you if ATYR is in your portfolio and how much it contributes.
Sign inMarket context
Smart money context
Holder IQ: MEDIUM
10 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryRed flags
Red flags: 0
Largest 13-F holders · Q2 2026
89 filers reported a long position in ATYR for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
74.8%
of the 38.9M shares 13-F filers reported
Moves vs Q1 2026
4 added5 trimmed
1 new
Net shares held
-36.3%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | Federated Hermes, Inc. | $5.1M · 8.5M shares | 8.5M | -19% |
| 2 | Vanguard Capital Management LLC | $2.3M · 3.8M shares | 3.8M | -0.1% |
| 3 | Gsa Capital Partners LLP | $2.1M · 3.5M shares | 3.5M | +105.1% |
| 4 | AQR Capital Management LLC | $1.6M · 2.6M shares | 2.6M | +426.3% |
| 5 | FMR LLC | $1.5M · 2.5M shares | 2.5M | -83.2% |
| 6 | BlackRock, Inc. | $1.1M · 1.8M shares | 1.8M | -71.6% |
| 7 | Kalehua Capital Management LLC | $1.1M · 1.8M shares | 1.8M | New |
| 8 | Jane Street Group, LLC | $1M · 1.7M shares | 1.7M | +3,448.9% |
| 9 | UBS Group AG | $914.1K · 1.5M shares | 1.5M | -60.4% |
| 10 | Morgan Stanley | $801.9K · 1.3M shares | 1.3M | +9.6% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of ATYR file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Nov 4, 2026 | Federated Hermes, Inc.13G · passive · amended | 0%under 5% |
| Aug 6, 2026 | FMR LLC13G · passive · amended | 2.5%under 5% |
| Jul 27, 2026 | BlackRock, Inc.13G · passive · amended | 1.8%under 5% |
| Mar 26, 2026 | Vanguard Group Inc13G · passive · amended | 0%under 5% |
Moves the factor model did not explain
How much of ATYR’s move accompanied the market and its measured style leanings, and how much was left? The residual is unexplained by this fitted model. It does not establish a cause, skill or future alpha.
Return split unavailable. A complete, reconciled model for every market session in this window is unavailable. Missing dates are not filled.
Link an account with dated transactions to see what share of your own holding’s move since its purchase-date close was unexplained, with long and short positions distinguished. Your private holdings never enter this public chart.
Dated model observations (20)
Daily percentage returns, not window contributions. Source: the same dated warehouse rows and model v1.2.0; observed 2026-11-14T16:16:56.502Z. Absent sessions are never interpolated; missing or failed inputs stay unavailable.
| Date | Stock | Market | Styles | Residual |
|---|---|---|---|---|
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable | |
| Unavailable | Unavailable | Unavailable | Unavailable |
How this split is calculated
Each day uses that day’s fitted market intercept and style exposures multiplied by that day’s published factor returns. Their sum plus the independently stored residual must reconcile to the stock return. Window effects are weighted by stock wealth at each day’s start and added; the stock return compounds. Every expected US market session must be present and pass source, identity, model and numerical checks. This retrospective fit is an explanation of measured returns, not evidence of causation or an investable forecast. The window ends at the latest published model session, which can lag the market; today’s unfinished session is excluded.
What insiders reported owning
Reading dated filing evidence…
Get the Full Analysis for ATYR
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.